QuantRx Biomedical Corporation (QTXB) Research

QuantRx Biomedical Corporation is engaged in the creation and marketing of its patented miniature pads (PADs) and related over-the-counter (OTC) products within the United States. Additionally, the company is developing genomic diagnostic tools for the laboratory market, leveraging its proprietary lateral flow technologies, including the RapidSense single-step lateral flow test. The company's PAD products are designed to address a range of medical conditions such as hemorrhoids, mild vaginal infections, urinary incontinence, menstrual hygiene, and other general medical needs. Key offerings include InSync, an interlabial pad for feminine hygiene. Another significant product is the Unique miniform, which comes in two forms: a medicated pad providing temporary relief from the itching and discomfort associated with hemorrhoids and minor vaginal infections, and an unmedicated pad for daily management of light urinary, vaginal, or anal leakage. Other treated miniform products are also part of their portfolio. Established in 1986, QuantRx Biomedical Corporation is headquartered in Tualatin, Oregon.

Market snapshot

Symbol
QTXB
Price
$0.00
Day change
+400.00%
Market cap
$118.0K
P/E ratio
-0.08x
52-week range
0.00001-0.004
Sector
Healthcare
Industry
Medical - Instruments & Supplies

Peer companies

  • Eden Empire Inc. (EDNEF)
  • MedMen Enterprises Inc. (MMNFF)
  • Miravant Medical Technologies Inc. (MRVT)
  • Invitae Corporation (NVTAQ)
  • PotNetwork Holdings, Inc. (POTN)
  • Propanc Biopharma, Inc. (PPCB)
  • RedHawk Holdings Corp. (SNDD)
  • StatSure Diagnostic Systems, Inc. (SSUR)

Recent insider activity

  • Hirschman Shalom — J-Other (150000 shares) on 2012-05-25
  • FLEMING WILLIAM H — J-Other (300000 shares) on 2012-05-25
  • ABRAMS MICHAEL S — trade (0 shares) on 2012-03-01
  • PINCO ROBERT G. — trade (0 shares) on 2010-04-30
  • MOONEY PATRICK T — trade (0 shares) on 2010-04-30

Open QuantRx Biomedical Corporation (QTXB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.